Intelligent Molecular Discovery Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.
MD Anderson UTHealth Graduate School of Biomedical Sciences , Houston, TX, USA.
Expert Opin Drug Discov. 2020 Sep;15(9):1025-1044. doi: 10.1080/17460441.2020.1767063. Epub 2020 May 26.
In recent years, computational polypharmacology has gained significant attention to study the promiscuous nature of drugs. Despite tremendous challenges, community-wide efforts have led to a variety of novel approaches for predicting drug polypharmacology. In particular, some rapid advances using machine learning and artificial intelligence have been reported with great success.
In this article, the authors provide a comprehensive update on the current state-of-the-art polypharmacology approaches and their applications, focusing on those reports published after our 2017 review article. The authors particularly discuss some novel, groundbreaking concepts, and methods that have been developed recently and applied to drug polypharmacology studies.
Polypharmacology is evolving and novel concepts are being introduced to counter the current challenges in the field. However, major hurdles remain including incompleteness of high-quality experimental data, lack of and assays to characterize multi-targeting agents, shortage of robust computational methods, and challenges to identify the best target combinations and design effective multi-targeting agents. Fortunately, numerous national/international efforts including multi-omics and artificial intelligence initiatives as well as most recent collaborations on addressing the COVID-19 pandemic have shown significant promise to propel the field of polypharmacology forward.
近年来,计算药物多靶性已经引起了人们的广泛关注,以研究药物的混杂性质。尽管面临巨大挑战,但全行业的努力已经促成了多种新型方法来预测药物多靶性。特别是,一些使用机器学习和人工智能的快速进展已经取得了巨大的成功。
本文作者全面介绍了当前药物多靶性研究的最新进展及其应用,重点介绍了自 2017 年我们的综述文章发表以来的报告。作者特别讨论了一些最近开发并应用于药物多靶性研究的新颖、开创性概念和方法。
药物多靶性正在发展,新的概念正在被引入以应对该领域当前的挑战。然而,仍然存在重大障碍,包括高质量实验数据的不完整性、缺乏用于表征多靶标药物的测定法和 assays、缺乏稳健的计算方法,以及难以确定最佳的靶标组合和设计有效的多靶标药物。幸运的是,许多国家/国际的努力,包括多组学和人工智能计划,以及最近为解决 COVID-19 大流行而开展的合作,都显示出了巨大的潜力,可以推动药物多靶性领域向前发展。